In a landmark shift for women’s health, the medical community has officially renamed polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS) to better reflect the condition’s complex hormonal and metabolic underpinnings. The change, announced via a global consensus process published in The Lancet, aims to address long-standing diagnostic delays affecting more than 170 million women worldwide. By moving away from a name that focuses solely on ovarian cysts, health professionals hope to improve clinical outcomes and reduce the stigma associated with this multifaceted endocrine disorder.
Why the Name Change to PMOS is Necessary
The term “polycystic ovary syndrome” has long been criticized by both patients and clinicians for being a misnomer. For decades, the name implied that the presence of pathological ovarian cysts was the primary driver of the condition, when in reality, many patients do not have cysts at all.
The renaming to polyendocrine metabolic ovarian syndrome (PMOS) is the result of a decade-long effort to modernize the medical lexicon. The U.S. National Institutes of Health first proposed a name change in 2012, but it required a rigorous global consensus involving patients, health professionals, and international medical organizations to finalize the transition.
